Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average) (2016 - 2025)

Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 15 years, with the latest figure at $161.0 million for Q1 2025.

  • For Q1 2025, Shares Outstanding (Weighted Average) rose 2.08% year-over-year to $161.0 million; the TTM value through Mar 2025 reached $161.0 million, up 2.08%, while the annual FY2020 figure was $159.4 million, 2.18% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2025 was $161.0 million at Ironwood Pharmaceuticals, up from $159.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $161.0 million in Q1 2025 and bottomed at $154.9 million in Q2 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $158.4 million (2024), against an average of $158.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 2.65% in 2024 before it rose 2.08% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $154.9 million in 2023, then increased by 2.65% to $159.0 million in 2024, then increased by 1.23% to $161.0 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Shares Outstanding (Weighted Average) are $161.0 million (Q1 2025), $159.0 million (Q2 2024), and $157.7 million (Q1 2024).